Hydroxypropyl beta-cyclodextrin compositions and methods
This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
1. A method of increasing ATG18 or ATG101 expression levels in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a mixture of hydroxypropyl beta-cyclodextrin (HPBCD) molecules, wherein the mixture comprises less than 1% beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”) and less than 1% unsubstituted beta-cyclodextrin (“DS-0”).
2. The method of claim 1 , wherein the mixture comprises at least 15% beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”).
3. The method of claim 1 , wherein the mixture comprises less than 3% unsubstituted beta-cyclodextrin (“DS-0”), beta-cyclodextrin substituted with one hydroxypropyl group (“DS-1”), and beta-cyclodextrin substituted with two hydroxypropyl group (“DS-2”), collectively.
4. The method of claim 1 , wherein the mixture comprises at least 65% beta-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”), beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”), and beta-cyclodextrin substituted with seven hydroxypropyl groups (“DS-7”), collectively.
5. The method of claim 3 , wherein the mixture comprises at least 65% beta-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”), beta-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”), and beta-cyclodextrin substituted with seven hydroxypropyl groups (“DS-7”), collectively.
6. The method of claim 1 , wherein the mixture comprises no more than 25% beta-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).
7. The method of claim 4 , wherein the mixture comprises no more than 25% beta-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).
8. The method of claim 1 , wherein the gene is ATG18.
9. The method of claim 4 , wherein the gene is ATG18.
10. The method of claim 1 , wherein the gene is ATG101.
11. The method of claim 4 , wherein the gene is ATG101.